BSE: 532540 NSE: Glaxosmithkline Pharmaceuticals ISIN: INE467B01029 SECTOR: IT Software Company Company’s Website: IPO Date & Price: July 29, 2004 | Rs.
Glaxosmithkline Pharmaceuticals Overview:
| Stock Symbol in BSE | Current Price | Market Cap. (Cr) | P/E Ratio | Current EPS | Stock Symbol in NSE |
|---|
Glaxosmithkline Pharmaceuticals Sector Performance and Peer Comparison with Sector Analysis:
Did You Know?
<Space for Feature Image>
- Glaxosmithkline Pharmaceuticals is the
- Its Belong to Group.
Balance Sheets & Profit & Loss Account:
| Year | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2016 | Mar 2015 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 |
|---|
Glaxosmithkline Pharmaceuticals Share Price Forecast Based on Current Growth +5/-5:
Share Price and EPS Forecast Based on Current Average Growth Rates:
| Next 5 Years (CG) | Next 10 Years (CG) | Next 20 Years (CG) |
|---|
Share Price and EPS Forecast Based on Current Average Growth Rates Plus 5%:
| Next 5 Years (CG+5%) | Next 10 Years (CG+5%) | Next 20 Years (CG+5%) |
|---|
Share Price and EPS Forecast Based on Current Average Growth Rates Minus 5%:
| Next 5 Years (CG-5%) | Next 20 Years (CG-5%) | Next 10 Years (CG-5%) |
|---|
Glaxosmithkline Pharmaceuticals Quarterly Result, Date & Street Estimate:
| Stock Symbol in NSE | Share Name | Quarter Results | Year | Street Estimates | Profits | Growth |
|---|
Fundamental Analysis of Glaxosmithkline Pharmaceuticals :
Glaxosmithkline Pharmaceuticals Share Long Term Investment Price Target:
| Long Term Investment Tagets | Price | Qnt.Ratio |
|---|
Glaxosmithkline Pharmaceuticals Fundamentals SWAT Analysis by AMT
Strengths, Weaknesses, Opportunities, and Threats of Glaxosmithkline Pharmaceuticals
S
- Strengths Analysis will coming Soon.
W
- Weakness Analysis will coming Soon.
O
- Opportunity Analysis will coming Soon.
T
- Threats Analysis will coming Soon.
Where we can See Glaxosmithkline Pharmaceuticals in Next 5 Year, 10 Year & 20 Year?
Technical Analysis of Glaxosmithkline Pharmaceuticals :
Glaxosmithkline Pharmaceuticals Share Weekly Swing Trading Price Target:
| Demand And Supply Zone | Support Levels | Support Price | Resistance Levels | Resistance Price |
|---|
Glaxosmithkline Pharmaceuticals Share Today Intraday Price Target:
| IntradayTarget Today [Short Selling] | IntradayTarget Today [Long Buying] |
|---|
FAQ on Glaxosmithkline Pharmaceuticals :
Yes, Glaxosmithkline Pharmaceuticals is India Number-1 IT Software company, with lots business potential in next few year. Its Fundamentally strong Stock we recommend to buy at around 20-25 PE Ration price target. Anyway This company is quite famous for Good Dividends.
Glaxosmithkline Pharmaceuticals is a Debt free company. Its can easily survived any down turn for 5-10 Quarter business growth.
Currently Glaxosmithkline Pharmaceuticals is Trading at P/E Ratio which is
Both and working as a
Do to Covid-19 pandemic Glaxosmithkline Pharmaceuticals Share drastically fall.
Its depend on when you and at what price you have buy this share, Glaxosmithkline Pharmaceuticals at 20-25 P/E Ration is a excellent buy call for long Term Investment.
Glaxosmithkline Pharmaceuticals ‘s Products/Projects:
| Products/Projects | Description/Valuation |
| A. | |
| B. | |
| C. |
IPO, Split, Bonus, Dividend Buyback History:
Glaxosmithkline Pharmaceuticals First IPO was initiate on July 29, 2004. equity shares were put on sale during the IPO with a price band of Rs -Rs per equity share.
[ninja_tables id=”79086″
Company Profile:
| CEO Name | Emma Walmsley |
| CFO Name | Mehernosh Kapadia |
| CEO Salary | N/A |
| Company Address | Dr. Annie Besant Road, Mumbai 400030, Maharashtra, India |
| Contact Number | +91-22-24959595 |
| Email Address | askus@gsk.com |
Declaration: Investing in the Stock market is full of Risky. AllMoneyTips.COM doesn’t give any guarantee or warranted on its investment advice. Do your research before investing in the stock market. Our Forecast and buying selling levels of stocks is based on price action and demand and supply zone. There is no guarantee come with our prediction. Take it as advice only. We are not responsible for your losses on your investments.